Madrigal Pharmaceuticals faces a legal investigation after disclosing a whistleblower complaint alleging the suppression of clinical data for its Rezdiffra drug, causing shares to drop over 8%.
A securities litigation firm is investigating Madrigal after the quarterly report on November 3, 2026 revealed a whistleblower complaint, filed October 9, 2026, alleging suppression of adverse liver-injury data and unreproducible efficacy data for Rezdiffra, the company's only approved drug. The stock already fell over 8% on that disclosure, and a formal investigation plus potential class action adds further downside and uncertainty.
Kessler Topaz Meltzer & Check, LLP has launched an investigation into Madrigal Pharmaceuticals regarding potential federal securities law violations. The probe follows a November 3, 2026 disclosure that a former executive filed a whistleblower complaint on October 9, 2026, alleging the suppression of adverse liver-injury data and unreproducible efficacy results for the company's drug, Rezdiffra.
On November 3, 2026 Madrigal disclosed that a former senior executive filed a whistleblower complaint on October 9, 2026 alleging the company suppressed adverse liver-injury data and presented efficacy results that could not be reconciled with source data for its only approved drug, Rezdiffra. The stock fell over 8% on the news and a securities litigation firm is now investigating possible violations of federal securities laws.
Investors who purchased Madrigal securities and experienced losses may have legal rights under federal securities laws, and the law firm is asking affected shareholders to come forward. If the investigation leads to a class action or the data allegations prove substantiated, further price pressure could follow.